Kinnate Biopharma IncChange company Symbol lookupSelect an option...KNTE Kinnate Biopharma IncTLOG TetraLogic Pharmaceuticals CorpJPM-K JPMorgan Chase & CoKLAC KLA CorpCNVY Convey Health Solutions Holdings IncEBAY eBay IncPRLX Parallax Health Sciences IncAXS AXIS Capital Holdings LtdSPNS Sapiens International Corporation NVSPCE Virgin Galactic Holdings IncGo
Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The Company has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. It is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.
|
|
|
|
| |
Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.